Is there a legal risk to criticizing Chinese companies?
Illustration by Valeria Petrone
On the day after Thanksgiving in 2020, Scott Paul got some bad news. BYD, the Chinese electric vehicle giant, was suing his organization and several of its employees in a defamation suit filed in U.S. federal court.
Data: Yahoo Finance
BYD, Paul knew, had deep pockets. The EV giant had a market cap of $75 billion at the time, with a staff of around 224,000 employees in China alone. By contrast, his organization was the Alliance for American Manufacturing (AAM), a D.C.-based non-profi
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from David Barboza, Pulitzer Prize-winning former Shanghai correspondent for The New York Times.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
Novo Nordisk, the maker of Ozempic, has enjoyed a China boom in recent years, commanding 77 percent of the market. But that kind of dominance isn’t likely to last, and Novo Nordisk’s challengers in China — both domestic and foreign — represent significant shifts in China’s pharmaceutical scene. Rachel Cheung reports on the tipping scales.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy